🔗 Share this article

A shadow market for unlicensed weight-loss medications is being driven by social media fitness personalities and vendors on communication apps, according to new investigations.

Investigational Drug Gaining Popularity Online

The experimental drug, which is still in research studies, is being promoted by social media influencers for its supposed weight-reducing effects. Viewers are urged to message these profiles privately for source information, while also obtaining promotional offers.

Active Trade on Messaging Platforms

Separately, a flourishing trade exists on Telegram, where communities with thousands of members share “before and after” photos, administration instructions and assertions of rapid UK delivery. Vendors market the substance there before redirecting customers to other platforms for purchases.

Learning About Retatrutide

Retatrutide is an experimental injectable developed by American pharmaceutical company Eli Lilly. The treatment affects three gut hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and glucagon. Early trials suggest it could assist individuals lose up to a quarter of their body weight. Nicknamed the “triple G”, the substance is being hailed digitally as the successor to Ozempic.

Healthcare Experts Express Concerns

However, physicians and pharmacists have cautions that the distribution of what is still an unlicensed medication in the UK is a cause for concern and could lead to users administering substances of uncertain source.

Some experts said the demand for retatrutide could be linked to the rising price of approved weight loss products such as Mounjaro.

Regulatory Position and Enforcement

Marketing the unapproved drug on social media or Telegram is prohibited in the UK, as it is an unapproved drug that must not be promoted or supplied for personal consumption under the Human Medicines Regulations 2012.

Some influencers attempt to circumvent the rules by calling to the drug as a “research chemical” or citing it as “not for human consumption”. Retatrutide is not a restricted substance, but promotion and distribution can still violate pharmaceutical, marketing, and consumer regulations, risking fines, prosecution or imprisonment.

Platform Response and Content Elimination

Based on the social media company, the service has removed violative material and banned related hashtags and search suggestions. The company said it was committed to keeping the platform safe and investing in strengthening enforcement strategies.

Digital Marketplace Activities

Research also discovered communities with up to 9,000 members marketing the experimental drug using the platform's built-in search feature, which functions like a public directory. Entering “retatrutide” instantly brings up channels with thousands of users, filled with photos of weight loss, glowing reviews and step-by-step instructions for preparing or injecting at residence.

After moments of joining one community, a seller posted WhatsApp details, where most transactions occur. The vendor provided an instruction manual and guaranteed shipping within 48 hours. When asked whether the substance was genuine, one vendor responded: “You can’t be sure.” Another shared a photo of a alleged laboratory certificate. Not one inquired about weight, health issues or past usage.

Item Information and Costs

Within these communities, messages display dark colored packages with postal service stickers, claiming to contain fresh supplies. One message stated: “It took eight of us to load them this morning.”

Customers can select between powder vials, prepared at home with sterile water, or ready-to-use pens usually priced at £160 for 20mg. When questioned how long a injector should last, sellers give contradictory responses varying between a few weeks to “depends on your body”.

Service Moderation and Security Measures

A spokesperson for the messaging service stated it regularly moderated harmful material on its service including material that promoted the “misuse of controlled medications”. The organization added that it eliminated “millions of pieces of harmful content each day”.

Healthcare Professional Warnings

“Individuals are injecting materials they can’t verify. Even if the research behind retatrutide is valid, these digital versions may not contain what they claim,” stated a pharmacy expert, the director of pharmaceutical services at Chemist4U.

A medical professional of an online medical service connected the surge in demand to recent cost increases for authorized weight-loss medications such as Mounjaro. “With prices rising, individuals are turning to online platforms. But fake treatments are highly risky. You can’t be certain what’s contained or whether the environment they were produced in was clean,” she said.

Her team has previously encountered individuals injured by personal administration from unconfirmed suppliers. “We recognize the disappointment, but buying from Telegram or communication platforms is gambling with your health,” stated Wyllie. “These substances could be contaminated or incorrectly dosed.”

Manufacturer Position

A representative from Eli Lilly said the substance was in phase 3 research studies and had not been reviewed or approved by any government authority globally. “Consequently at this time no one can market [it] for personal consumption,” they explained, adding that any item “falsely representing itself as a Lilly investigational product not yet approved … may expose patients to possibly significant health risks”.